Nu-med Plus, INC

Nu-Med Plus, Inc. has completed the acquisition of Avid Gold Ltd and entered into an agreement to acquire Canadian gold properties, diversifying its business into gold exploration and development.

Nu-Med Plus, Inc. announced its entry into a Share Exchange Agreement to acquire 100% of Avid Gold Ltd., a UK-based private limited company, in a transaction valued at approximately $100,000 plus 4,500,000 shares of Series A Preferred Stock.

Nu-Med Plus, Inc. has terminated its acquisition agreement with YourSpace America, Inc. due to the failure of YourSpace to provide audited financial statements, leading to the resignation of the appointed CEO and the appointment of the Chairman as the new CEO.

Nu-Med Plus, Inc. has finalized its merger with YourSpace America, Inc., resulting in a change of control and the appointment of William R. Russ Colvin as CEO.

Nu-Med Plus, Inc. has agreed to merge with YourSpace America, Inc. in a share exchange agreement, making YourSpace a wholly-owned subsidiary.

NU-MED PLUS, an early-stage medical device company, reported a net loss for Q3 2025 and expressed substantial doubt about its ability to continue as a going concern without significant new capital.

NU-MED PLUS, an early-stage medical device company, reported a net loss and significant working capital deficiency, raising substantial doubt about its ability to continue operations without immediate capital infusion.

Nu-Med Plus, a medical device company, reported no revenue and a net loss of $19,933 for the quarter ended March 31, 2025, highlighting the company's reliance on external funding to continue operations and product development.

Nu-Med Plus, Inc. reported its third quarter 2024 results, showing no revenue and a net loss, while also announcing the termination of its merger agreement with YourSpace America, Inc.

Nu-Med Plus reports no revenue and a net loss for the second quarter of 2024, while awaiting the completion of the YourSpace America merger.

Nu-Med Plus reported a net loss for Q1 2024 and announced a merger with YourSpace America, Inc., which will result in a change of control and a shift in business focus.

Nu-Med Plus, Inc. files its annual report on Form 10-K for the fiscal year ended December 31, 2025, detailing its ongoing development of nitric oxide delivery systems and its precarious financial situation.

Nu-Med Plus, Inc. files its Form 10-K for the year ended December 31, 2024, reporting a net loss and highlighting substantial doubt about its ability to continue as a going concern without additional funding.

Nu-Med Plus, Inc. reports its 2023 annual results, highlighting ongoing product development challenges and a significant net loss, while also expressing substantial doubt about the company's ability to continue as a going concern.